[go: up one dir, main page]

PE20060716A1 - Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas - Google Patents

Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas

Info

Publication number
PE20060716A1
PE20060716A1 PE2005000304A PE2005000304A PE20060716A1 PE 20060716 A1 PE20060716 A1 PE 20060716A1 PE 2005000304 A PE2005000304 A PE 2005000304A PE 2005000304 A PE2005000304 A PE 2005000304A PE 20060716 A1 PE20060716 A1 PE 20060716A1
Authority
PE
Peru
Prior art keywords
active ingredient
dry powder
microparticles
pharmaceutical formulations
powder inhalers
Prior art date
Application number
PE2005000304A
Other languages
English (en)
Inventor
Roberto Bilzi
Angela Armanni
Daniela Cocconi
Rossella Musa
Roberto Rastelli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060716(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE20060716A1 publication Critical patent/PE20060716A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA FORMULACION EN POLVO A USAR EN INHALADOR DE POLVO SECO DONDE AQUELLA COMPRENDE: (A) MICROPARTICULAS DE UN INGREDIENTE ACTIVO TAL COMO 8-HIDROXI-5-[(1R)-1-HIDROXI-2-[[(1R)-2-(4-METOXIFENIL)-1-METILETIL]AMINO]ETIL-2(1H)-QUINOLINONA O SU CLORHIDRATO Y EL COMPUESTO CHF 4226; (B) UN CORTICOSTEROIDE COMO BUDESONIDA, FLUTICASONA, FLUNISOLIDA, BECLOMETASONA, ENTRE OTROS; (C) UN MATERIAL PARA USO FISIOLOGICO LACTOSA MONOHIDRATO, ARABINOSA, DEXTROSA, ENTRE OTROS; (D) UN LUBRICANTE COMO ACIDO ESTEARICO, LAURILSULFATO DE SODIO, ALCOHOL ESTEARILICO, ENTRE OTROS. LA MEDIANA DEL DIAMETRO DE LA MASA (MMD) DE DICHAS MICROPARTICULAS COMPRENDE ENTRE 2 Y 15 MICRONES; AL MENOS UN 10% DE DICHAS MICROPARTICULAS TIENE UN DIAMETRO DE MASA MAYOR QUE 0,5 MICRONES Y LA RELACION ENTRE EL INGREDIENTE ACTIVO Y EL EXCIPIENTE COMPRENDE ENTRE 1:5 Y 1:100 POR CIENTO EN PESO. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE OBSTRUCCIONES REVERSIBLES DE LAS VIAS AEREAS, INFLAMACION E HIPERREACTIVIDAD
PE2005000304A 2004-03-17 2005-03-17 Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas PE20060716A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04006430 2004-03-17

Publications (1)

Publication Number Publication Date
PE20060716A1 true PE20060716A1 (es) 2006-07-25

Family

ID=34962706

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000304A PE20060716A1 (es) 2004-03-17 2005-03-17 Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas

Country Status (20)

Country Link
US (1) US8153104B2 (es)
EP (1) EP1729728B1 (es)
KR (1) KR20060130216A (es)
CN (1) CN1942172B (es)
AR (1) AR049010A1 (es)
AU (1) AU2005224008B2 (es)
BR (1) BRPI0508170A (es)
CA (1) CA2560226C (es)
ES (1) ES2566618T3 (es)
HK (1) HK1101346A1 (es)
JO (1) JO3102B1 (es)
MA (1) MA28514B1 (es)
MX (1) MXPA06010593A (es)
NO (1) NO342481B1 (es)
NZ (1) NZ549870A (es)
PE (1) PE20060716A1 (es)
RU (1) RU2371171C2 (es)
TN (1) TNSN06277A1 (es)
WO (1) WO2005089717A1 (es)
ZA (1) ZA200607700B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
CL2008000500A1 (es) * 2007-02-19 2008-09-05 Cipla Ltd Combinacion farmaceutica que comprende una combinacion de dos o mas broncodilatadores o una combinacion de al menos un broncodilatador y al menos un corticosteroide; uso para tratar o prevenir una enfermedad respiratoria; e inhalador que comprende di
EP2191821A1 (en) 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
TWI491416B (zh) * 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
EP2470167A4 (en) * 2009-08-27 2013-08-14 Stc Unm METHOD AND SYSTEM FOR DOSING AND COATING INHALATION POWDER ON SUPPORT PARTICLE
EP2360147A1 (en) * 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
CN104257610A (zh) * 2010-04-01 2015-01-07 奇斯药制品公司 用于制备可吸入干粉所用的载体颗粒的方法
DE102011102614A1 (de) * 2011-05-27 2012-11-29 Roland Nied Verfahren zum Betrieb einer Strahlmühle sowie Strahlmühle
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
KR101786586B1 (ko) * 2012-01-25 2017-10-18 키에시 파르마슈티시 엣스. 피. 에이. 흡입에 의한 투여를 위한 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
SG11201405243TA (en) * 2012-02-28 2014-09-26 Iceutica Holdings Inc Bvi Inhalable pharmaceutical compositions
CN104470503A (zh) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
JP5087182B1 (ja) * 2012-06-13 2012-11-28 クリニプロ株式会社 吸入用パウダーの製造方法
CA2912485A1 (en) 2013-03-13 2014-10-09 Forest Laboratories Holdings Limited Micronized pharmaceutical compositions
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
CN105338960B (zh) 2013-07-11 2019-06-04 奇斯药制品公司 用于吸入施用的包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
SMT202000280T1 (it) 2014-09-09 2020-07-08 Vectura Ltd Formulazione comprendente glicopirrolato, metodo ed apparecchiatura
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
GB201911517D0 (en) * 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
JP7649441B2 (ja) * 2019-12-16 2025-03-21 シージェン インコーポレイテッド 賦形剤の高速液体クロマトグラフィー定量法
US20210353650A1 (en) * 2020-05-18 2021-11-18 Cai Gu Huang Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441740B1 (de) * 1990-01-29 1993-09-22 Ciba-Geigy Ag Verfahren und Vorrichtung zur Dosierung eines feinkörnigen Pulvers
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU2001281113B2 (en) * 2000-08-07 2006-07-20 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6587025B2 (en) * 2001-01-31 2003-07-01 Vishay Dale Electronics, Inc. Side-by-side coil inductor
WO2005004846A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug

Also Published As

Publication number Publication date
TNSN06277A1 (en) 2007-12-03
NO342481B1 (no) 2018-05-28
MA28514B1 (fr) 2007-04-03
WO2005089717A1 (en) 2005-09-29
MXPA06010593A (es) 2007-02-16
AU2005224008A1 (en) 2005-09-29
JO3102B1 (ar) 2017-09-20
RU2371171C2 (ru) 2009-10-27
ES2566618T3 (es) 2016-04-14
CN1942172A (zh) 2007-04-04
CN1942172B (zh) 2010-10-06
CA2560226C (en) 2013-07-23
AU2005224008B2 (en) 2010-09-16
NZ549870A (en) 2010-05-28
CA2560226A1 (en) 2005-09-29
EP1729728B1 (en) 2016-03-16
BRPI0508170A (pt) 2007-08-07
ZA200607700B (en) 2008-05-28
AR049010A1 (es) 2006-06-21
NO20064161L (no) 2006-10-17
US20070202053A1 (en) 2007-08-30
US8153104B2 (en) 2012-04-10
KR20060130216A (ko) 2006-12-18
HK1101346A1 (en) 2007-10-18
RU2006133038A (ru) 2008-03-20
EP1729728A1 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
PE20060716A1 (es) Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas
JP7015331B2 (ja) ロフルミラストｎ－酸化物の吸入によって自己免疫、呼吸器性および炎症性の障害を処置する方法
AR055363A1 (es) Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion
ES2664175T3 (es) Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa
CN110381960A (zh) 作为抗微生物剂的增强剂的碳酸氢盐
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
KR101621676B1 (ko) 천식의 병세악화를 예방 및/또는 치료하기 위한 포르모테롤 및 베클로메타손 디프로피오네이트를 포함하는 조성의 용도
TW201039833A (en) Novel combinations
BR112015020443A8 (pt) formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica
US20160310410A1 (en) Pharmaceutical compositions comprising arformoterol and glycopyrronium
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
KR20220097447A (ko) 클로파지민의 조성물, 이를 포함하는 조합물, 이의 제조 방법, 이를 포함하는 용도 및 치료 방법
US20220105119A1 (en) Delivery of aerosolized micromolar composition concentrations
WO2017077488A1 (en) An inhalable fixed dose powder composition comprising glycopyrronium and formoterol
WO2019110099A1 (en) Inhalable clofazimine formulation
WO2007008157A1 (en) New combination 2
JP7102147B2 (ja) 放射線療法に起因する皮膚損傷の予防における使用のための、クロニジンおよび／またはクロニジン誘導体
WO2020240350A1 (en) An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate
JP2009185006A (ja) 点鼻・点眼剤
KR20150138160A (ko) 로플루밀라스트 n- 옥사이드의 흡입에 의한 자가면역, 호흡 및 염증성 장애의 치료방법
WO2015063669A1 (en) Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
FC Refusal